United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Acquires 9,526 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

Key Points

• United Super Pty Ltd increased its holdings in UnitedHealth Group by 8.1% during the first quarter, acquiring an additional 9,526 shares to reach a total of 127,114 shares, valued at approximately $66.58 million.
• CEO Patrick Hugh Conway sold 589 shares of the company for about $179,645, while Director Timothy Patrick Flynn purchased 1,533 shares valued at approximately $491,786.
• UnitedHealth Group reported a quarterly EPS of $4.08, missing the expected $4.45, with revenue of $111.62 billion, which was slightly below the consensus estimate of $111.75 billion.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its position in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 8.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,114 shares of the healthcare conglomerate's stock after acquiring an additional 9,526 shares during the quarter. UnitedHealth Group makes up about 2.7% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's investment portfolio, making the stock its 13th largest holding. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's holdings in UnitedHealth Group were worth $66,576,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of UNH. Brighton Jones LLC boosted its stake in UnitedHealth Group by 176.2% in the 4th quarter. Brighton Jones LLC now owns 44,249 shares of the healthcare conglomerate's stock valued at $22,384,000 after purchasing an additional 28,231 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of UnitedHealth Group by 137.1% in the fourth quarter. Revolve Wealth Partners LLC now owns 4,019 shares of the healthcare conglomerate's stock valued at $2,033,000 after acquiring an additional 2,324 shares in the last quarter. Bank Pictet & Cie Europe AG raised its stake in UnitedHealth Group by 3.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 263,655 shares of the healthcare conglomerate's stock worth $133,373,000 after purchasing an additional 9,872 shares in the last quarter. Bryce Point Capital LLC acquired a new position in shares of UnitedHealth Group during the 4th quarter worth approximately $475,000. Finally, Yoffe Investment Management LLC acquired a new stake in shares of UnitedHealth Group in the fourth quarter valued at approximately $1,232,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Patrick Hugh Conway sold 589 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $305.00, for a total transaction of $179,645.00. Following the completion of the transaction, the chief executive officer owned 10,398 shares of the company's stock, valued at approximately $3,171,390. The trade was a 5.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Timothy Patrick Flynn purchased 1,533 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was bought at an average cost of $320.80 per share, with a total value of $491,786.40. Following the purchase, the director owned 6,033 shares in the company, valued at approximately $1,935,386.40. This represents a 34.07% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 109,408 shares of company stock worth $31,607,768. Company insiders own 0.28% of the company's stock.

UnitedHealth Group Price Performance

UNH opened at $237.40 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85. The firm has a market cap of $215.36 billion, a P/E ratio of 10.29, a PEG ratio of 1.56 and a beta of 0.43. UnitedHealth Group Incorporated has a fifty-two week low of $234.60 and a fifty-two week high of $630.73. The firm has a 50-day moving average of $296.86 and a 200 day moving average of $416.24.

UnitedHealth Group (NYSE:UNH - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share for the quarter, missing the consensus estimate of $4.45 by ($0.37). UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%. The firm had revenue of $111.62 billion during the quarter, compared to analysts' expectations of $111.75 billion. During the same period last year, the business posted $6.80 EPS. The company's revenue was up 12.9% compared to the same quarter last year. On average, research analysts expect that UnitedHealth Group Incorporated will post 29.54 EPS for the current year.

UnitedHealth Group Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 24th. Stockholders of record on Monday, June 16th were given a dividend of $2.21 per share. This is an increase from UnitedHealth Group's previous quarterly dividend of $2.10. The ex-dividend date was Monday, June 16th. This represents a $8.84 dividend on an annualized basis and a dividend yield of 3.7%. UnitedHealth Group's dividend payout ratio (DPR) is presently 38.30%.

Analyst Ratings Changes

UNH has been the subject of several recent analyst reports. Morgan Stanley cut their target price on UnitedHealth Group from $563.00 to $374.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Mizuho reduced their price objective on UnitedHealth Group from $515.00 to $350.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. KeyCorp dropped their target price on shares of UnitedHealth Group from $400.00 to $350.00 and set an "overweight" rating for the company in a report on Wednesday. HSBC reiterated a "reduce" rating and set a $270.00 price objective (down from $490.00) on shares of UnitedHealth Group in a research report on Wednesday, May 21st. Finally, Oppenheimer decreased their target price on shares of UnitedHealth Group from $400.00 to $325.00 and set an "outperform" rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $373.52.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.